Modification of the thromboxane: prostacyclin ratio alters the severity of reperfusion arrhythmias and postischemic damage in long-term, irreversibly injured myocardium. In this study, the effects of the thromboxane synthetase inhibitor dazmegrel and the thromboxane receptor antagonist BM 13.505 on myocardial postischemic funlctional recovery and preservation of tissue adenine nucleotides was examined after a 15-minute episode of ischemia followed by 3 hours of reperfusion (myocardial stunning). Dazmegrel (3 or 8 mg/kg) or BM 13.505 (10 mg/kg) was given 15 minutes before coronary occlusion and compared with a control group in barbital-anesthetized dogs. Regional segment shortening (percent segment shortening, sonomicrometry), regional myocardial blood flow (microspheres), and coronary venous eicosanoid and high-energy phosphate levels (biopsies after 3 hours of reperfusion) were measured. Areas at risk, regional myocardial blood flow, and regional segment shortening during coronary occlusion were similar in all groups. Dazmegrel (3 mg/kg) attenuated the decrease in endocardial and midmyocardial adenosine 5'-triphosphate, and both doses significantly improved regional segment shortening during reperfusion. Coronary venous thromboxane levels were significantly decreased throughout the experiment in both dazmegrel-treated groups, and thromboxane levels were significantly elevated in the control group 3 hours after reperfusion. Prostacyclin, measured in the form of its main metabolite, 6-keto-prostaglandin F,,,, did not change significantly in the control group throughout the experiment, but it was markedly increased in dazmegrel groups throughout reperfusion, particularly in the dazmegrel group receiving 3 mg/kg. BM 13.505 exerted no beneficial effects on postischemic function or metabolism. In conclusion, after a reversible ischemic insult, postischemic recovery of function and metabolic status was not enhanced by preocclusion treatment with a thromboxane receptor blocker, and thus, the beneficial effects of thromboxane synthesis inhibition on postischemic abnormalities was not due to a reduction in thromboxane but was the result of endoperoxide shunting and a subsequent increase in prostacyclin. Therefore, thromboxane does not appear to be an important mediator of reversible ischemia-reperfusion damage. (Circulation 1988;78:450-461) S ince the discovery of a strongly vasospastic h, compound, rabbit aorta-contracting substance,' that is released during anaphylaxis, and since the subsequent identification2 of the main component as the arachidonic acid metabolite throm-
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Prostacyclin, measured in the form of its main metabolite, 6-keto-prostaglandin F,,,, did not change significantly in the control group throughout the experiment, but it was markedly increased in dazmegrel groups throughout reperfusion, particularly in the dazmegrel group receiving 3 mg/kg. BM compound, rabbit aorta-contracting substance,' that is released during anaphylaxis, and since the subsequent identification2 of the main component as the arachidonic acid metabolite throm-boxane A2, there have been many studies suggesting a role for thromboxane as a pathophysiological mediator in thrombosis,3 vasospasm,45 arrhythmias, 6 and in the progression of ischemic damage after coronary artery occlusion. Inhibition of thromboxane synthesis3 and blockade of thromboxane receptors7 have been shown to inhibit cyclic-flow variations in severely narrowed coronary arteries. Although thromboxane is a potent vasoconstrictor in vitro5 and in vivo,8 it may be premature to attribute clinical vasospasm to an increase in thromboxane because inhibition of thromboxane synthesis by OKY-046, a thromboxane synthetase inhibitor, has not resulted in a decrease in the number or length of ischemic episodes in patients with vasospastic angina. 9 Several studies indicate that thromboxane may, in part, mediate arrhythmias observed during coronary artery occlusion and reperfusion,6,10 whereas others11'12 have provided evidence that thromboxane may not be involved in arrhythmias occurring during acute myocardial ischemia.
Previous studies with various thromboxane inhibitors demonstrated efficacious responses in reducing both myocardial creatine kinase13-16 and aminonitrogen14,15 loss, as indexes of ischemic damage, in cats and rats after long-term ischemic insults. Also, the thromboxane synthetase inhibitor CV-4151 has been shown to decrease infarct size after 60 minutes of coronary occlusion and 60 minutes of reperfusion in dogs. '7 Because inhibition of thromboxane synthesis has been shown to have beneficial effects in many models of experimental ischemia, blockade of thromboxane receptors may offer a potential theoretical advantage in reducing ischemic damage because a receptor blocker would also antagonize prostaglandin endoperoxides and possibly 6-keto-prostaglandin F2a (6- microspheres were injected into the left atrium followed by a 6-ml saline flush. Before microsphere administration, reference blood flows from the right femoral artery were collected at the rate of 6.8 ml/min for 2-3 minutes.
At the completion of each blood-flow collection, the LAD was reoccluded, and 10 ml India ink was injected into the LAD distal to the occlusion site to delineate the area subjected to ischemia, and saline was simultaneously injected at a similar pressure (100 mm Hg) into the left atrium. The heart was then removed, stored overnight in 10% formalin, subsequently sectioned into epicardium, midmyocardium, and endocardium of both the normal (three pieces) and ischemic regions (five pieces), and the tissue samples were weighed. All samples were counted in a gamma counter (1195, Searle Analytic, Elk Grove, Illinois) to determine the activity of each isotope in each tissue and reference blood-flow sample. Myocardial blood flow was calculated with a preprogrammed computer to obtain the true activity of each isotope in individual samples, and tissue blood flow was determined with the equation: Qmn = Qr X Cm/Cr, where Qm is myocardial blood flow (ml/min/g), Qr is rate of withdrawal of the reference blood-flow sample (6.8 ml/min), Cr is activity of the reference blood-flow sample (cpm), and Cm is activity of the tissue sample (cpm/g). Transmural tissue blood flow was calculated as the weighted average of the three layers in each region. Myocardial blood-flow distribution (endocardial: epicardial blood-flow ratio) was calculated by dividing the average endocardial flow of each region by the average epicardial flow. The ischemic area transmural flow normalized to the nonischemic area was also calculated.
Prostanoid Measurements
Blood samples (4 ml), obtained at various times from a local coronary vein draining the ischemicreperfused area, were collected into ice-chilled plastic tubes containing 0.2 ml 2.8 mg/ml ethylenediaminetetraacetic acid as anticoagulant and 0.8 ml 0.1 mg/ml indomethacin to prevent ex vivo generation of prostanoids. Blood samples were centrifuged at 2,500 rpm for 10 minutes, and the resulting plasma was stored at -700 C for later analyses. Thromboxane B2 and 6-keto-PGFI, the stable breakdown products ofthromboxane A2 and prostacyclin, respectively, were measured with radioimmunoassay (New England Nuclear, Boston, Massachusetts).
Metabolism Biopsy
Immediately before killing the dogs at 3 hours postreperfusion, small areas in normal and postischemic regions were painted with methylene blue dye. Transmural tissue samples were obtained within the dye sites by the use of a cylindrical cutting tool mounted onto a hand drill. The sample was clamped immediately between two large aluminum blocks precooled in liquid nitrogen. The frozen biopsies were divided into three approximately equal transmural sections: epicardium (identified by the methylene blue dye), midmyocardium, and endocardium. The frozen sections were weighed and homogenized at 40 C in 6% perchloric acid with a Tekmar tissue homogenizer. Extracts were neutralized with 5 M K2C03, and the supernatant was used for biochemical analyses as performed previously.22,30 Analyses were performed at 340 nm on a Gilford 250 spectrophotometer. An aliquot of neutralized extract was used in a coupled enzymatic reaction to determine phosphocreatine and adenosine 5'-triphosphate (ATP), and in a separate coupled reaction, adenosine 5'-diphosphate (ADP) and adenosine 3,5'-monophosphate (AMP) were determined. Tissue slices from normal and postischemic regions were weighed and dried to constant weight at 950 C in preweighed vials. The total tissue water was expressed as milliliters of water per 100 grams of dry tissue. Tissue nucleotides were expressed as micromoles per gram of dry weight, and the total adenine nucleotide pool was calculated as the sum of ATP, ADP, and AMP in each layer.
Experimental Protocol
After surgical preparation and stabilization, pretreatment control measurements of hemodynamics, myocardial segment function, blood flow, blood gases, and prostanoids were obtained ( Figure 1 In a separate series of three dogs, anesthetized and ventilated as described above, aortic systolic pressures were monitored through a pressure transducer catheter inserted into the aorta from the carotid artery. The thromboxane analogue U46619 was administered intravenously in increasing doses through a femoral vein cannula. Doses were increased when pressure had stabilized after the previous administration (approximately 10-15 minutes). After administration of the highest dose and a return of pressure to predrug levels, BM Although the incidence of ventricular fibrillation after reperfusion after treatment with dazmegrel was less than that in the control group, this difference was not statistically significant. Analysis of data was performed for 10 control dogs and 10 dazmegrel-treated dogs at each of the two doses studied and for nine BM 13.505-treated dogs.
Hemodynamics
The hemodynamics of all groups during pretreatment control, at 10 minutes after drug treatment, at 12 minutes of occlusion and at 180 minutes after reperfusion are summarized in Table 1 . There were no significant differences in any hemodynamic variable between control, dazmegrel-treated dogs, and BM 13.505-treated dogs at any time, and there were no differences within any group throughout the experiment, with the exception of dP/dt in the BM 13.505 group, which was significantly decreased during reperfusion compared with the control group (p<O.OS).
Intravenous infusion of the thromboxane agonist U46619 resulted in marked increases in aortic systolic pressure (10 and 50 ,g U46619 lead to increases of 14 13 .505 group, 0.93 ± 0.06 ml/min/g). However, by 3 hours after reperfusion, transmural tissue flow in the nonischemic area of the dazmegrel-8 group had significantly decreased to 0.69 ± 0.08 ml/min/g, whereas there were no significant changes in flow within the normal areas in the control, dazmegrel-3, or BM 13.505 groups. Although flow in the BM 13.505-treated animals tended to be lower in the ischemic-reperfused region, no significant differences in blood flow, endocardium: epicardium ratio, and ischemic-area transmural flow normalized to the nonischemic region were present before and during occlusion (Table 2) , thus demonstrating that all groups were subjected to comparable degrees of ischemia. There were no differences present in tissue blood flow between the groups during reperfusion.
Prostanoid Measurements
Coronary venous thromboxane levels in control and dazmegrel groups are shown in Figure 2 . Although thromboxane levels in the control group increased significantly by 3 hours after reperfusion Figure 4) ; however, this ratio was markedly decreased in dazmegreltreated dogs before and during occlusion and during reperfusion. There were no differences between dazmegrel-3 and dazmegrel-8 groups in the thromboxane B2 :6-keto-PGFia ratio. Reperfusion (min) FIGURE 3 . Plot of coronary venous levels of 6-ketoprostaglandin F,,, the main metabolite of prostacyclin (prostaglandin I2), measured at pretreatment control (PTC), 10 minutes after dazmegrel or saline administration, 12 minutes ofcoronary occlusion (Occ), and various times after reperfusion. *p<0.05 vs. PTC within a group based on absolute values. tp<0.05 vs. the control group.
Myocardial Segment Function
There were no significant differences in subendocardial wall function in the LCx-perfused, nonischemic area between any group throughout the experiment. Segment shortening in this area remained relatively constant throughout 3 hours of reperfusion.
In the LAD-perfused area, % SS in the sham group ( Figure 5) 5 . Plot of percent segment shortening of pre-26 ± 11%) ( Figure 6 ). treatment control (PTC) in the ischemic-reperfused region at PTC, 10 minutes after drug administration (Drug), 12 High-Energy Phosphates minutes of occlusion (Occ), and at various times after Regional tissue levels of ATP, total adenine nuclereperfusion. Time-course curves for sham (n=8), control otide pool, and phosphocreatine at 3 hours after (n-10), and dazmegrel-treated groups (n=10, each group) reperfusion are shown in reperfused area was also decreased. In contrast, there was a reduction in the loss of ATP and total adenine nucleotides compared with the control group (p<O.OS) in the endocardium of the reperfused area in the dazmegrel-3 group. In contrast to the rebound increase in phosphocreatine observed in the epicardium, midmyocardium, and endocardium in the ischemic-reperfused region of the control group, no rebound increase in phosphocreatine was seen in the epicardium or midmyocardium of dogs treated with dazmegrel-3 or dazmegrel-8 (Table 3 ). There were no differences between control and BM 13.505 groups in myocardial content of adenine nucleotides in any layer. Similar to the reperfusioninduced rebound increase in phosphocreatine observed in the control group, a significant increase was also seen in the BM 13.505 group (Table 3) . Total tissue water in ischemic-reperfused regions was increased in all layers at 3 hours after reperfusion. Dazmegrel pretreatment (both groups) appeared to decrease the edema in endocardial layers; however, differences were not significant, whereas tissue edema was not affected by BM 13 [13] [14] [15] [16] [17] Several studies suggest that thromboxane is arrhythmogenic during acute myocardial ischemia, particularly during reperfusion.6' 0 However, in those studies, regional myocardial blood flow was not measured, and the possibility exists that the beneficial influence on arrhythmias after synthesis inhibition was secondary and was due to a decrease in ischemic damage. Results of the present study did not demonstrate a significant decrease in reperfusion-induced ventricular fibrillation in dogs pretreated with dazmegrel or BM 13.505. The reasons for the difference between these results and those of previous studies are unknown but may be related to the length of the occlusion period, species differences, or simply may be due to sample size.
In addition to antiarrhythmic properties, various thromboxane inhibitors have been shown to attenuate the loss of myocardial creatine kinase and nitrogenous compounds from the ischemic myocardium, to attenuate the rise in plasma creatine kinase activity, and to decrease the ischemia-induced ST segment elevation after permanent coronary occlusions.' Also, the thromboxane synthetase inhibitor CV-4151 has been shown to decrease infarct size in a 1 hour occlusion-1 hour reperfusion model.'7 Note that in these previous studies there were no observed drug effects on hemodynamics, myocardial oxygen demand, or myocardial oxygen supply. Cardioprotective actions were attributed to an attenuation of catecholamine release, an endoperoxide shunting to potentially beneficial prostanoids after the use of synthesis inhibitors, or an inhibition of thromboxane-mediated vasoconstriction, platelet aggregation, or cellular lysis. [13] [14] [15] [16] [17] 32 All previous studies except one,33 that have investigated the pathophysiological role of thromboxane in ischemic and postischemic myocardial dysfunction have been performed in the presence of tissue necrosis (i.e., irreversible injury). In a model using multiple 3-minute ischemic periods, preocclusion treatment with dazmegrel resulted in a decrease in the release of inorganic phosphate, lactate, and potassium from coronary sinus blood during early reperfusion and in a reduction of the oxygen debt acquired during ischemia.33 Beneficial effects were attributed, in part, to enhanced flow to ischemic areas and, in part, to an increase in prostacyclin. Although increased regional blood flow was not observed in the present study, differences may be due to the technique used to measure flow or the time during occlusion that flow was measured. Although it has been implied in a previous study'3 that dazmegrel exhibited a metabolic cardioprotective action, regional myocardial function and myocardial high-energy phosphate levels during reperfusion were not measured then. The results of the present study with dazmegrel indicate that thromboxane may play a role in the prolonged postischemic abnormalities in both function and metabolism after a transient ischemic insult in the absence of cell death (myocardial stunning). However, results with the thromboxane receptor antagonist, BM 13.505, suggest that thromboxane is not involved as a mediator of reversible postischemic dysfunction. BM 13.505 did not affect hemodynamics or regional myocardial blood flow, and both of these variables were similar to those of the control and dazmegreltreated groups.
Our finding of preserved myocardial high-energy phosphate levels at 3 hours of reperfusion after low-dose dazmegrel treatment is consistent with the observation that pretreatment with dazmegrel decreases the release of inorganic phosphate during early reperfusion.33 Although a poor correlation between recovery of ATP and myocardial function during reperfusion has been shown,34 it has recently been found that decreased coupling of myofibrillar creatine kinase and adenosine triphosphatase (ATPase) may be responsible for functional abnormalities in the stunned myocardium. 35 This was shown by a calculated reduction in free ADP concentration below the Michaelis constant (K,m) for myofibrillar creatine kinase as well as a slightly reduced activity. If indeed myocardial stunning is due, in part, to this phenomenon, the dazmegrelrelated increase in adenine nucleotide levels may result in an increase in free ADP concentrations for creatine kinase or may result in an increased amount of localized ATP for myosin ATPase. On the other hand, the high dose of dazmegrel did not preserve adenine nucleotides, and yet it still resulted in improved functional recovery, which suggests that a reduction in the loss of ATP is not the primary mechanism of action of dazmegrel in this model. The attenuation of the phosphocreatine rebound in the dazmegrel-treated groups may reflect an increased creatine kinase activity that serves to replenish an enhanced rate of ATP hydrolysis sec-ondary to an increase in myocardial function. The increase in prostacyclin observed in our study after thromboxane synthesis inhibition is well documented6 17, 32, 45 and appears to be a likely mechanism for the beneficial effects of dazmegrel in the stunned myocardium. Also, enhanced production of PGD2, PGF2a, and PGE2 after inhibition of thromboxane synthesis has also been suggested. 45 An increase in the production of these prostanoids, as well as prostacyclin, would be possible in endothelium or leukocytes by conversion of endoperoxides released from platelets or from arachidonic acid released from tissues as a result of membrane damage. Prostacyclin could potentially inhibit many thromboxane-mediated events, such as vasoconstriction, platelet aggregation, cell membrane destabilization, catecholamine release, and profibrillatory action.44,46 By altering the ratio of thromboxane to prostacyclin in favor of the vasodilatory prostacyclin, myocardial perfusion at the microcirculatory level may also be enhanced.
We have previously demonstrated that infusion of the stable prostacyclin mimetic, iloprost, was able to significantly enhance postischemic function in the stunned myocardium when the drug was administered either before occlusion or during reperfusion.22 In addition to mechanisms previously mentioned, potential benefit from PGI2 in the stunned myocardium could be through the inhibition of neutrophil-derived superoxide anion production. 22, 47 Treatment with the high dose of dazmegrel (8 mg/kg) resulted in less preservation of adenine nucleotides, slightly less functional recovery by 3 hours of reperfusion, and less of an increase in 6-keto-PGFia levels compared with the lower dose (3 mg/kg). Although the reasons for these observations are unknown, they may be related to either a nonspecific inhibition of prostacyclin synthase or cyclooxygenase by the higher dose or an endoperoxide reorientation to prostanoids other than prostacyclin. Because other prostanoids were not measured in the present study, evaluation of these hypotheses is not possible. Also, the effects of PGF2a, PGD2, and PGE2 on the functional recovery of the stunned myocardium are unknown. However, the greater endoperoxide shunting to prostacyclin by the lower dose of dazmegrel is in accordance with the finding that receptor blockade shared none of the beneficial effects of synthetase inhibition and the hypothesis that rather than thromboxane being involved as a mediator of myocardial stunning, blood cells. 42 Although the thromboxane-receptor 459 synthesis inhibition is beneficial because of the increase in prostacyclin. Thus, one would predict that the greater increase in prostacyclin with the lower dose of dazmegrel would lead to greater postischemic recovery.
In conclusion, inhibition of thromboxane synthetase by dazmegrel, but not thromboxane receptor blockade by BM 13.505, significantly enhanced the recovery of regional myocardial function (%SS) in the stunned myocardium. This cardioprotective effect was achieved in the absence of changes in myocardial oxygen supply-demand variables and without preventing the loss of systolic wall function that occurs during ischemia. Dazmegrel, but not BM 13.505, resulted in the preservation of myocardial adenine nucleotides within the ischemicreperfused myocardium. Thus, although blockade of thromboxane actions by antagonism of receptors does not enhance postischemic function or metabolism, inhibition of thromboxane synthesis and subsequent prostanoid redirection to prostacyclin augments postischemic recovery after a reversible ischemic insult and demonstrates a lack of pathophysiological significance for thromboxane as a mediator of the stunning phenomenon.
